Noevir Holdings Co., Ltd. (4928) AI Stock Analysis

• Market Cap: ¥142.94B
• Dividend Yield: 5.38%
• Average Volume (3M): 50.66K
• Price to Earnings (P/E): 17.8
• Beta (1Y): 0.43
• Revenue Growth: 1.51%
• EPS Growth: 5.48%
• Country: JP
• Employees: 1,369
• Sector: Consumer Defensive
• Sector Strength: 76
• Industry: Household & Personal Products
• EPS (TTM): 48.83
• Shares Outstanding: 34,156,624
• 10 Day Avg. Volume: 58,660
• 30 Day Avg. Volume: 50,656
• PEG Ratio: -43.82
• Price to Book (P/B): 3.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 22.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 80 Outperform
• Price Target: ¥4,853.00 ▲( 15.96% Upside)

Noevir Holdings Co., Ltd. receives a strong overall score due to its robust financial performance and reasonable valuation supported by a high dividend yield. Technical analysis shows moderate positive momentum, enhancing the stock's attractiveness in the market. Earnings call and corporate events data were not available for analysis.

Noevir Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Noevir Holdings Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of cosmetics, pharmaceuticals, and health-food products. The company operates through various segments, including Cosmetics, Pharmaceuticals, and Others. Its core products include skincare, makeup, and nutritional supplements, designed to enhance beauty and wellness. Noevir is known for its high-quality, innovative formulas and its commitment to research and development, leveraging both traditional and modern scientific approaches to create effective and safe products.

How the Company Makes Money

Noevir Holdings Co., Ltd. generates revenue through its diversified product lines across several key segments. The primary revenue stream comes from the Cosmetics segment, which includes the sale of skincare, makeup, and beauty products. This segment benefits from a well-established distribution network, including direct sales channels and retail partnerships. Additionally, Noevir earns income from its Pharmaceuticals segment, which includes the development and sale of health-related products and over-the-counter medications. The company also capitalizes on its Health Food segment, offering nutritional and dietary supplements. Moreover, Noevir's investments in research and development contribute to its competitive edge, ensuring a steady pipeline of new and innovative products. Strategic partnerships and collaborations also play a role in expanding its market reach and enhancing its brand presence globally.

Noevir Holdings Co., Ltd. Financial Statement Overview

Summary

Noevir Holdings Co., Ltd. demonstrates strong financial health with consistent revenue growth and robust profit margins. The company maintains a solid balance sheet with minimal debt and efficient cash flow conversion. While further growth in free cash flow could enhance financial flexibility, the company is well-positioned in its industry.

Income Statement

The income statement of Noevir Holdings Co., Ltd. shows strong performance with consistent revenue growth, evidenced by a 4.6% growth in total revenue from 2023 to TTM 2024. The company maintains healthy margins with a gross profit margin of 67.1% and a net profit margin of 12.4% in TTM. EBIT and EBITDA margins are also strong at 17.3% and 18.8%, respectively, indicating operational efficiency.

Balance Sheet

Noevir Holdings has a robust balance sheet with a low debt-to-equity ratio of 0.02, reflecting minimal leverage and financial risk. The equity ratio is high at 66.1%, suggesting strong asset backing. Return on Equity (ROE) is moderate at 16.9%, indicating efficient use of equity to generate profits.

Cash Flow

The cash flow statement reveals healthy cash generation with a free cash flow to net income ratio of 0.82, indicating strong conversion of income to cash. However, free cash flow growth has been modest at 1.1% from 2023 to TTM 2024. The operating cash flow to net income ratio stands at 0.87, reflecting solid cash flow management.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
64.01B	63.82B	62.55B	61.14B	51.27B	51.84B
	Gross Profit
42.95B	43.16B	42.56B	42.09B	33.03B	33.08B
	EBIT
11.06B	11.42B	11.02B	10.12B	8.56B	8.06B
	EBITDA
12.06B	12.43B	12.24B	11.57B	10.05B	9.76B
	Net Income Common Stockholders
7.94B	7.97B	7.67B	7.59B	6.38B	5.62B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.27B	29.22B	28.88B	29.75B	31.10B	29.46B
	Total Assets
71.02B	76.47B	77.25B	76.78B	80.45B	80.05B
	Total Debt
806.00M	828.00M	914.00M	1.00B	1.11B	1.22B
	Net Debt
-12.47B	-28.39B	-27.97B	-28.74B	-29.99B	-28.23B
	Total Liabilities
23.52B	22.57B	24.04B	24.40B	28.22B	27.81B
	Stockholders Equity
46.97B	53.48B	52.79B	52.05B	51.93B	51.98B
Cash Flow		Free Cash Flow
6.50B	8.11B	6.57B	5.23B	8.63B	5.67B
	Operating Cash Flow
6.92B	9.12B	7.62B	5.84B	9.06B	7.31B
	Investing Cash Flow
-8.27B	1.52B	-3.54B	-255.00M	-416.00M	-1.61B
	Financing Cash Flow
-7.90B	-7.71B	-7.49B	-7.38B	-7.18B	-6.96B

Noevir Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4185.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Positive. The current price of 4185 is below the 20-day moving average (MA) of 4201.00, below the 50-day MA of 4185.70, and below the 200-day MA of 4735.34, indicating a neutral trend. The MACD of 13.43 indicates Positive momentum. The RSI at 53.47 is Neutral, neither overbought nor oversold. The STOCH value of 35.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4928.

Noevir Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4928	80 Outperform	¥142.94B	17.84		5.38%	1.51%	5.48%
4912	74 Outperform	$426.51B	20.04	7.58%	1.73%	2.30%	33.87%
4927	70 Outperform	$292.46B	39.16	4.49%	3.66%	-0.74%	-25.66%
Sector *	65 Neutral	$8.84B	14.90	4.69%	203.33%	3.49%	-1.84%
4967	56 Neutral	$376.23B	35.20	5.17%	1.87%	-8.36%	-38.35%
4911	55 Neutral	¥911.63B	496.62		1.75%	-1.33%	-139.30%

Noevir Holdings Co., Ltd. Corporate Events

Noevir Holdings Reports Mixed Financial Results for First Half of Fiscal Year 2025

Noevir Holdings reported its consolidated financial results for the first six months of the fiscal year ending September 30, 2025, showing a slight increase in net sales by 1.3% compared to the previous year. However, the company faced a decline in operating and ordinary income, with operating income dropping by 7.3% and ordinary income by 3.5%. Despite these challenges, net income attributable to owners of the parent increased by 1.7%. The equity ratio also decreased from 69.9% to 66.5%, indicating changes in the company’s financial position. The company maintained its dividend forecast, signaling stability in shareholder returns.